

Use of vincristine for the intralesional treatment of cutaneous Kaposi disease lesions: experience on 10 patients

Cillo Francesco

Italy



Abstract

Kaposi's Sarcoma is a tumor of endothelial cells caused by a viral infection (HHV-8). It, in its classical form (cKS), is particularly common in the Mediterranean area. It manifests with red-violet nodules and plaques located especially in the lower limbs. Among the topical therapies the intralesional use of vincristine, although off-label, can be used for the nodular limited forms.

Our study includes ten patients, HIV negative, suffering from the classical form of Kaposi's Sarcoma. 35 nodules were recruited and two categories were identified: Small (diameter less than 0.8 cm) and Large (diameter greater than 0.8 cm) for which either 0,05 mL and 0.1 mL of vincristine were injected respectively. The therapy was carried out following a 42-day cycle, at the end of which the progress of the nodules was evaluated according to the ACTG criteria.

In total of the 35 nodules: 23 (65.71%) were resolved at the end of treatment, 12 (34.28%) were persistent even with a reduction in diameter. In no case has an increase in the nodular diameter been noted. We therefore believe that the intralesional use of vincristine can be considered at the first line of the treatment of Kaposian nodules, qualifying as more effective and safer than other local treatments.

Biography

Cillo F. has completed his studies of Medicine with highest marks at the age of 28 years from University of Naples Federico II, IT with a thesis entitled "Diagnostic therapeutic treatment of Kaposi's Sarcoma with prevalent cutaneous exposure: experience of dermatology in Federico II University" (2019). He did an undergraduated internship at Memorial Sloan Kettering Hospital of NY for an oncodermatological management of patients suffering from Kaposi's sarcoma, with attention to the differences between the correlated HIV forms, typical of the American continent, and the HIV free ones, typical of the Mediterranean area. He has two publications on Kaposi's Sarcoma: "Atypical Manifestations in Classic Kaposi Sarcoma: Case Series of two Patients HIV – Negative" (Review: Open Access Maced J Med Sci 2019); "Use of vincristine for the intralesional treatment of cutaneous Kaposi disease lesions: experience on 10 patients" (Review: Annales de Dermatologie et de Vénéréologie 2019).

Publications

Peduto T, Cillo F, Nappa P, Delfino M, Fabbrocini G, Ferrillo M., Open Access Maced J Med Sci. 2019 Mar 27;7(6):1021-1024

Prigigallo MI, Križnik M, Paola D, Catalano D, Gruden K, Finetti-Sialer MM, Cillo F, Viruses. 2019 Nov 27;11(12):1100

Prigigallo MI, Melillo MT, Bubici G, Dobrev PI, Vankova R, Cillo F, Veronico P, Pest Manag Sci. 2019 Aug;75(8):2251-2263

International Meet on Dermatologists and Cosmetologists, London, UK | 9th-10th June, 2020

Citation: Cillo Francesco, *Use of vincristine for the intralesional treatment of cutaneous Kaposi disease lesions: experience on 10 patient*, Dermatology Summit 2020, International Meet on Dermatologists and Cosmetologists, London, UK, June 9-10, 2020, 03:03-6